



# Memorandum

## Direct Acting Antiviral (DAA) Medications & Treatment of Hepatitis C

**Date: September 5, 2014**

Hepatitis C has been identified as a significant etiology of chronic liver disease, associated co-morbidities, need for liver transplant and death. Newly approved direct acting antiviral (DAA) medications have changed recommendations and therapeutic guidelines. This document will provide you with the information needed when requesting a prior authorization (PA) for the DAAs.

The clinical criteria and all forms are located on the EOHHS website under the *Pharmacy* section at the following link:

<http://www.eohhs.ri.gov/ProvidersPartners/GeneralInformation/ProviderDirectories/Pharmacy/PharmacyPriorAuthorizationProgram.aspx>.

### Process

#### Step 1 - Application for Preferred Provider Status (PA22-PPS)

- Prescriber to complete and submit to (401) 784-3889
- Once approved, the prescriber will be considered “preferred” and it will *not be necessary* to send the preferred provider form with every PA request

#### Step 2- Prior Authorization Direct Acting Antiviral Medications (PA22)

- Prescriber to complete and submit to (401) 784-3889
- Prescriber will be notified upon completion of PA review

#### Step 3 - Sample Patient Contract (PA22- Patient Contract)

- Prescriber to maintain a patient contract as part of medical record
- Sample form which provider can consider for use